Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Among patients with ER-positive, HER2-negative advanced breast cancer, treatment with imlunestrant led to significantly longer progression-free survival than standard therapy among those with <i>ESR1</i> mutations but not in the overall population. Imlunestrant-abemaciclib significantly improved progression-free survival as compared with imlunestrant, regardless of <i>ESR1</i>-mutation status. (Funded by Eli Lilly; EMBER-3 ClinicalTrials.gov number, NCT04975308.).
Authors
- Giuseppe Curigliano (ORCID: https://orcid.org/0000-0003-1781-2518)
- María de la Luz García Tinoco
- François‐Clément Bidard (ORCID: https://orcid.org/0000-0001-5932-8949)
- Patrick Neven (ORCID: https://orcid.org/0000-0002-1434-9460)
- Eriko Tokunaga (ORCID: https://orcid.org/0000-0002-1640-5315)
- Xuejing Aimee Wang
- Jorge Luis Martinez Rodriguez (ORCID: https://orcid.org/0009-0008-8686-469X)
- Nadia Harbeck (ORCID: https://orcid.org/0000-0002-9744-7372)
- Chiun‐Sheng Huang (ORCID: https://orcid.org/0000-0002-6557-211X)
- André P. L. Mattar (ORCID: https://orcid.org/0000-0001-5973-623X)
- Antonio Llombart‐Cussac (ORCID: https://orcid.org/0000-0003-4515-8293)
- Joohyuk Sohn (ORCID: https://orcid.org/0000-0002-2303-2764)
- C. Laue
- Kamnesh R. Pradhan (ORCID: https://orcid.org/0000-0002-1488-5992)
- Shanshan Cao (ORCID: https://orcid.org/0000-0001-7280-1657)
- Joyce O’Shaughnessy (ORCID: https://orcid.org/0000-0002-2955-5523)
- Chih‐Chiang Hung (ORCID: https://orcid.org/0000-0002-7164-9179)
- Komal L. Jhaveri (ORCID: https://orcid.org/0000-0003-0472-1254)
- Lisa A. Carey (ORCID: https://orcid.org/0000-0003-2388-4649)
- Cristina Saura (ORCID: https://orcid.org/0000-0001-8296-5065)
- Rikiya Nakamura (ORCID: https://orcid.org/0000-0002-4349-9046)
- Elgene Lim (ORCID: https://orcid.org/0000-0001-8065-8838)
- M.L. Casalnuovo
- Lillian M. Smyth (ORCID: https://orcid.org/0000-0002-0986-9285)
- Qingyuan Zhang (ORCID: https://orcid.org/0000-0002-1763-9412)
- Philippe Aftimos
- Emily Barrett
- Manuel Ruíz Borrego
- Sung-Bae Kim
Institutions
- University of North Carolina at Chapel Hill (US)
- Ulsan College (KR)
- Hebron University (PS)
- Memorial Sloan Kettering Cancer Center (US)
- Garvan Institute of Medical Research (AU)
- Harbin Medical University (CN)
- Eli Lilly (United States) (US)
- University of Milan (IT)
- Yonsei University (KR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Cornell University (US)
- Université Paris-Saclay (FR)
- Asan Medical Center (KR)
- Institut Jules Bordet (BE)
- Villa Maria Hospital (UG)
- Baylor University Medical Center (US)
- University of Ulsan (KR)
- Taichung Veterans General Hospital (TW)
- National Hospital Organization Kyushu Cancer Center (JP)
- Women's Hospital (US)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Chiba Cancer Center (JP)
- Hospital Arnau de Vilanova (ES)
- Centro Medico Nacional Siglo XXI (MX)
- National Taiwan University Hospital (TW)
- Mylan (Switzerland) (CH)
- Hospital Universitario Virgen del Rocío (ES)
- Vall d'Hebron Institute of Oncology (ES)
- European Institute of Oncology (IT)
- Ludwig-Maximilians-Universität München (DE)
- Tecnológico de Monterrey (MX)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1056/nejmoa2410858
- Citations
- 118
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 49.43
Funders
- Eli Lilly and Company